Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure

The coronavirus disease (COVID-19) pandemic is a global health priority. Given that cardiovascular diseases (CVD) are the leading cause of morbidity around the world and that several trials have reported severe cardiovascular damage in patients infected with SARS-CoV-2, a substantial number of COVID...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Heart failure reviews 2021-03, Vol.26 (2), p.371-380
Hauptverfasser:	Razeghian-Jahromi, Iman, Zibaeenezhad, Mohammad Javad, Lu, Zhibing, Zahra, Elyaspour, Mahboobeh, Razmkhah, Lionetti, Vicenzo
Format:	Artikel
Sprache:	eng
Schlagworte:	ACE2 Angiotensin II Angiotensin-converting enzyme 2 Angiotensin-Converting Enzyme 2 - antagonists & inhibitors Angiotensin-Converting Enzyme 2 - physiology Angiotensin-converting enzyme inhibitors Angiotensin-Converting Enzyme Inhibitors - adverse effects Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiology Cardiovascular diseases Cell surface Clinical trials Congestive heart failure Coronary artery disease Coronaviruses COVID-19 COVID-19 - chemically induced COVID-19 - epidemiology Diuretics Enzymes Heart failure Heart Failure - drug therapy Humans Medicine Medicine & Public Health Morbidity Muscle contraction Pandemics Peptidyl-dipeptidase A Public health Renin Renin-Angiotensin System - drug effects Renin-Angiotensin System - physiology Risk Assessment Severe acute respiratory syndrome coronavirus 2 Therapeutic targets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!